Effects of Isotretinoin on CYP2D6 Activity
Sponsor: National Institute of General Medical Sciences (NIGMS)
A PHASE4 clinical study on CYP2D6 Polymorphism, this trial is completed. The trial is conducted by National Institute of General Medical Sciences (NIGMS) and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Dec 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE4
▶ Show 4 earlier versions
-
Oct 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE4
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of General Medical Sciences (NIGMS)
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .